Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIRMOST: adjuvant firmonertinib versus placebo in resected EGFR uncommon-mutant NSCLC
CTR20250929Phase 3Active
- Sponsor
- Allist Pharmaceuticals
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of furmonertinib in non-small cell lung cancer (NSCLC), sponsored by Allist Pharmaceuticals. Started May 2025; status: active.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20250929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250929.